Novel Gene Therapy Solution for Abnormal Fuel Metabolism and Diminished Contractile Function of the Diabetic Heart
- Technology Benefits
- There are currently no specific approaches available for correcting abnormal fuel flux and improving contractile function of the diabetic heart. Utilizing this novel gene therapy approach, cardiac function could potentially be returned to normal in spite of persistent diabetes in the patient.
- Detailed Technology Description
- UCSD researchers have discovered a novel gene therapy to correct the abnormal fuel flux in diabetic cardiac myocytes and significantly increase the contractile performance of the heart.
- Others
-
State Of Development
Work in animal models has demonstrated feasibility of the approach, and expression of the transgene in human cardiac muscle cells has been accomplished.
Intellectual Property Info
This technology is available for licensing.
Tech ID/UC Case
24104/2014-256-0
Related Cases
2014-256-0
- *Abstract
-
Heart disease is a major factor in the mortality and morbidity associated with diabetes. Disturbances in key signaling pathways in cardiac myocytes alters fuel flux, increasing the diabetic heart’s reliance on fatty acids as fuel. This impaired substrate metabolism contributes to contractile dysfunction of the cardiac muscle ultimately leading to heart failure.
- *Principal Investigator
-
Name: Wolfgang Dillmann
Department:
Name: Jorge Suarez
Department:
- Country/Region
- USA
For more information, please click Here
